Literature DB >> 26314083

ADAM17 and CD56low CD16low NK cells.

Rizwan Romee1, Jeffrey S Miller2.   

Abstract

Entities:  

Keywords:  ADAM17 expression; CD16low; CD56low; cell development; natural killer cell function

Mesh：

Substances：

Year:  2015        PMID： 26314083      PMCID： PMC5004437          DOI： 10.3324/haematol.2015.129213

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets.

Authors:  O Penack; C Gentilini; L Fischer; A M Asemissen; C Scheibenbogen; E Thiel; L Uharek
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

2.  CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases.

Authors:  B Grzywacz; N Kataria; M R Verneris
Journal:  Leukemia       Date:  2007-02       Impact factor: 11.528

3.  ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.

Authors:  Laurie Lajoie; Nicolas Congy-Jolivet; Armelle Bolzec; Valérie Gouilleux-Gruart; Elodie Sicard; Hsueh Cheng Sung; Frank Peiretti; Thierry Moreau; Henri Vié; Béatrice Clémenceau; Gilles Thibault
Journal:  J Immunol       Date:  2013-12-13       Impact factor: 5.422

4.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

5.  Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Daniel J Weisdorf; Lisbeth A Guethlein; John P Klein; Tao Wang; Chap T Le; Steven G E Marsh; Daniel Geraghty; Stephen Spellman; Michael D Haagenson; Martha Ladner; Elizabeth Trachtenberg; Peter Parham; Jeffrey S Miller
Journal:  Blood       Date:  2010-06-25       Impact factor: 22.113

6.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.

Authors:  Antonio Curti; Loredana Ruggeri; Alessandra D'Addio; Andrea Bontadini; Elisa Dan; Maria Rosa Motta; Sara Trabanelli; Valeria Giudice; Elena Urbani; Giovanni Martinelli; Stefania Paolini; Fiorenza Fruet; Alessandro Isidori; Sarah Parisi; Giuseppe Bandini; Michele Baccarani; Andrea Velardi; Roberto M Lemoli
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

7.  Multifunctional human CD56 low CD16 low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients.

Authors:  Helena Stabile; Paolo Nisti; Stefania Morrone; Daria Pagliara; Alice Bertaina; Franco Locatelli; Angela Santoni; Angela Gismondi
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

8.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Authors:  Jeffrey S Miller; Yvette Soignier; Angela Panoskaltsis-Mortari; Sarah A McNearney; Gong H Yun; Susan K Fautsch; David McKenna; Chap Le; Todd E Defor; Linda J Burns; Paul J Orchard; Bruce R Blazar; John E Wagner; Arne Slungaard; Daniel J Weisdorf; Ian J Okazaki; Philip B McGlave
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

9.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Raul C Ribeiro; Stanley Pounds; Barbara Rooney; Teresa Bell; Ching-Hon Pui; Wing Leung
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

10.  NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).

Authors:  Rizwan Romee; Bree Foley; Todd Lenvik; Yue Wang; Bin Zhang; Dave Ankarlo; Xianghua Luo; Sarah Cooley; Mike Verneris; Bruce Walcheck; Jeffrey Miller
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.